Rare diseases
Investigational molecules
Locations
Recruiting trials first
6 clinical trials in this condition
Germany
AustriaAustriaGermanyIn short
Generalized tonic-clonic seizures are intense episodes that cause the body to stiffen, shake violently, and lose consciousness—all within just a few minutes. These seizures, once called grand mal seizures, are among the most recognizable and feared types of seizures, yet with proper treatment and management, many people can reduce their frequency and live full lives.
The main goal of treating generalized tonic-clonic seizures is to stop or reduce the frequency of these episodes, prevent injuries during seizures, and improve the overall quality of life for those affected. Treatment approaches vary significantly depending on whether the seizures occur as isolated events or as part of a recurring condition like epilepsy. Each patient's treatment plan needs to be carefully tailored based on the underlying cause, the frequency of seizures, age, other health conditions, and how well previous treatments have worked.
For many people, treatment begins once a diagnosis is confirmed. However, not everyone who experiences a single tonic-clonic seizure will require long-term treatment. If the seizure was triggered by a temporary condition—such as a high fever, metabolic imbalance, or substance withdrawal—addressing that specific cause may be all that's needed. But when seizures recur without an obvious trigger, indicating epilepsy, ongoing treatment becomes essential.
Medical professionals follow established guidelines from organizations like the International League Against Epilepsy to categorize and treat these seizures appropriately. The treatment landscape includes both well-established medications that have been used for decades and newer approaches currently being tested in clinical trials. Additionally, lifestyle modifications, surgical options, and dietary interventions may play important roles in managing this condition.
The foundation of treatment for recurrent generalized tonic-clonic seizures rests on anti-epileptic drugs (also called anticonvulsants). These medications work by stabilizing the electrical activity in the brain, preventing the sudden bursts of abnormal signals that trigger seizures. The goal is not necessarily to eliminate all seizures—though that's ideal—but to reduce their frequency and severity to a manageable level while minimizing side effects.
Valproic acid has long been considered a first-line medication for people who experience multiple seizure types, including tonic-clonic seizures. This drug treats a broad spectrum of seizure types and has proven effective in many patients. A large study called the SANAD trial supported the use of valproate as a primary choice for generalized seizures. However, valproic acid comes with significant considerations. It can cause weight gain, liver problems, and is known to cause serious birth defects, so it's generally avoided in women of reproductive age unless no other options are suitable.
For seizures that start in one part of the brain and spread to become generalized (called focal to bilateral tonic-clonic seizures), medications like phenytoin and carbamazepine have been reasonable choices among older anti-epileptic drugs. These medications have been used for decades and their effects are well understood. However, they require regular blood tests to monitor drug levels and can interact with many other medications, including birth control pills, which makes them less convenient for some patients.
Newer anti-epileptic medications have entered clinical practice and offer advantages in terms of side effects and drug interactions. Lamotrigine, topiramate, zonisamide, and levetiracetam are often preferred because they work as well or better than older drugs and generally cause fewer long-term side effects. These medications don't require as much blood monitoring and have fewer interactions with other drugs. Levetiracetam, for example, has become popular because it's relatively well-tolerated and can be started quickly in urgent situations.
Phenobarbital is one of the oldest anti-seizure medications still in use. While it remains effective and inexpensive, its use has declined because it can affect memory, concentration, and alertness. For children especially, these cognitive side effects can interfere with learning and development, making other options more attractive when possible.
Perampanel is a more recent addition approved specifically as an add-on treatment for primary generalized tonic-clonic seizures in adults and children aged 12 years and older. It has also shown good effectiveness in reducing seizures that start as focal seizures and become generalized. This medication works by blocking receptors in the brain that are involved in seizure activity.
For people with Lennox-Gastaut syndrome, a severe form of epilepsy that includes tonic-clonic seizures, medications like rufinamide and clobazam have been approved as add-on therapies. Clobazam, which has been used worldwide for many years, has also shown effectiveness for primary generalized tonic-clonic seizures beyond just Lennox-Gastaut syndrome.
When seizures prove resistant to multiple medications, felbamate may be considered as a last-resort option. This drug can be very effective, but it carries serious potential side effects including liver damage and blood disorders. Because of these risks, patients taking felbamate require very careful monitoring with regular blood tests to check liver function and blood cell counts.
The duration of treatment varies considerably. Some people may need to take anti-epileptic medications for just a few years, while others require lifelong treatment. Doctors generally recommend continuing medication for at least two years after the last seizure before considering whether to reduce or stop treatment. The decision to discontinue medication must be made carefully, weighing the risk of seizure recurrence against the burden of ongoing medication and its side effects.
Side effects are an important consideration when choosing and continuing anti-epileptic medications. Common side effects include drowsiness, dizziness, weight changes, mood changes, and difficulty concentrating. Some medications can affect bone health over time, leading to osteoporosis. The older first-generation medications—phenytoin, carbamazepine, phenobarbital, and valproic acid—carry known risks for birth defects, which is a crucial consideration for anyone who might become pregnant.
Beyond medications, other established treatments play important roles for some patients. Vagus nerve stimulation involves surgically implanting a device that sends regular electrical pulses to the vagus nerve in the neck, which then affects brain activity and can reduce seizure frequency. This option is typically considered when medications haven't provided adequate control.
The ketogenic diet, a high-fat, low-carbohydrate eating plan, has been used especially in children whose seizures don't respond well to medications. This diet changes how the body produces energy and appears to have anti-seizure effects through mechanisms that aren't fully understood. The diet requires careful medical supervision and precise meal planning, as even small deviations can affect its effectiveness.
Surgical treatment may be an option for carefully selected patients whose seizures originate from a specific area of the brain that can be safely removed. However, true generalized tonic-clonic seizures that start on both sides of the brain simultaneously are generally not suitable for surgical removal of brain tissue. Surgery is more often considered for focal seizures that become generalized.
Beyond the standard treatments already available, researchers continue to investigate new approaches to treating generalized tonic-clonic seizures. These investigations happen through clinical trials, which are carefully designed research studies that test whether new treatments are safe and effective. Clinical trials progress through different phases, each answering specific questions about a potential treatment.
Phase I trials focus primarily on safety. They typically involve small numbers of participants and aim to determine safe dosing ranges and identify side effects. These early-stage trials help researchers understand how the human body processes a new drug and whether it's safe enough to proceed with further testing.
Phase II trials expand to larger groups and begin evaluating whether the treatment actually works. These trials often compare the new treatment to a placebo or to standard treatment to see if it provides benefits. Researchers look at whether the treatment reduces seizure frequency, how well patients tolerate it, and what dose seems most effective. Phase II trials are crucial for determining whether a new approach is promising enough to move forward to more extensive testing.
Phase III trials involve much larger groups of patients across multiple locations and provide definitive evidence about effectiveness and safety. These trials typically compare the new treatment directly against current standard treatments to see if it offers advantages. Positive Phase III results are usually required before regulatory agencies like the FDA approve a new medication for general use.
Phase IV trials continue even after a drug is approved and marketed. These studies monitor long-term effects, identify rare side effects that might not have appeared in earlier trials, and compare the new treatment with other available options in real-world settings.
Many clinical trials for epilepsy treatments are conducted at major medical centers in the United States, Europe, and increasingly around the world. Some trials specifically recruit patients whose seizures haven't responded adequately to existing medications—a situation called refractory or drug-resistant epilepsy. Other trials may test new medications in specific age groups, such as children or elderly adults, to ensure safety and effectiveness across different populations.
Patient eligibility for clinical trials typically depends on factors like the type and frequency of seizures, previous treatments tried, age, other health conditions, and whether the person is willing and able to follow the study requirements. Many trials require participants to keep detailed seizure diaries and attend regular monitoring appointments. While participating in a clinical trial offers potential access to cutting-edge treatments, it also involves uncertainty since the new treatment might not work better than existing options, and unknown side effects might emerge.
Various approaches are being explored in clinical research for seizure management, though specific details about experimental drugs and their mechanisms for generalized tonic-clonic seizures require up-to-date information from clinical trial registries and recent medical literature. The field continues to evolve as researchers investigate new molecular targets, refine existing drug formulations, and explore innovative delivery methods that might improve seizure control while reducing side effects.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
